Post-occlusive reactive hyperemia in basal cell carcinoma and its potential application to improve the efficacy of solid tumor therapies.
Tumor hypoxia is a hallmark of malignant tumors, and is a major factor in the resistance to anti-cancer therapies, particularly radiotherapy.  Indeed, tumor blood flow often fluctuates, and thus the oxygen supply is often reduced, thereby inducing tumor hypoxia.  We decided to explore whether post-occlusive reactive hyperemia, a physiological reaction known to occur in normal tissues, could be induced through a malignant tumor, basal cell carcinoma (BCC), in which angiogenesis occurs, as in all malignant tumors.  Skin blood flow was measured in twelve patients with BCC, using Laser Speckle Contrast Imaging to determine BCC perfusion after three minutes of vascular occlusion, induced by limb tourniquet for limb tumors (4 BCC), and/or by clamping the pedicle of a skin flap with the BCC at its center, for other tumor locations (12 BCC). We demonstrated for the first time that post-occlusive reactive hyperemia occurs in malignant tumors in humans.  BCC perfusion curves were similar to those of healthy skin, characterized by a peak of hyperemia after reperfusion followed by a progressive return to the pre-occlusion perfusion level.  Induction of post-occlusive reactive hyperemia in malignant tumors is therefore a novel investigational approach that could lead to a new adjuvant tool to increase the efficacy of chemotherapy and radiotherapy, respectively through the synchronized temporary increase of tumor perfusion and oxygenation.
Department of Surgery, Institut Curie, René Huguenin Hospital, Saint-Cloud, France. julien.reyal@gmail.com
Julien
J
Reyal
Nicolas
N
Lebas
Emmanuelle
E
Fourme
Thierry
T
Guihard
Catherine
C
Vilmer
Périg
P
Le Masurier
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000758:Anesthesia; D002280:Basal Cell Carcinoma / Q000098:blood supply* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006262:Health; D006801:Humans; D006940:Hyperemia / Q000473:pathology* / Q000503:physiopathology; D017078:Laser-Doppler Flowmetry; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010477:Perfusion; D012044:Regression Analysis; D012867:Skin / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D012878:Skin Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*; D014664:Vasodilation / Q000187:drug effects
D008012:Lidocaine